Drug Trial Radar · NCT07907783
Phase 2 Efficacy and Safety of PP405 in Adult Females With Androgenetic Alopecia
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Nov 10, 2026
Primary completion
Sep 2027
Study completion Mar 2028
Sponsor
- Lead sponsor
- Pelage Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to evaluate safety and efficacy of PP405 in adult female participants with androgenetic alopecia
Conditions
- Androgenetic Alopecia
Interventions
PP405 0.05% Topical GelDrug
Medicated topical gel containing PP405 0.05%
Vehicle Topical GelDrug
Topical gel
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in non-vellus target area hair countTime frame: Week 24
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Burke Pharmaceutical Research
Hot Springs, Arkansas · Recruiting
DelRicht Research (Experience Dermatology)
Atlanta, Georgia · Recruiting
Equity Medical, LLC
New York, New York · Recruiting
DelRicht @Mt Pleasant Dermatology
Mt. Pleasant, South Carolina · Recruiting
DelRicht Research @Harpeth Valley Dermatology
Smyrna, Tennessee · Recruiting
Institution: Delricht Research @Lockhart
Prosper, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.